[go: up one dir, main page]

PL2482849T3 - Skojarzona immunoterapia w leczeniu nowotworu - Google Patents

Skojarzona immunoterapia w leczeniu nowotworu

Info

Publication number
PL2482849T3
PL2482849T3 PL10821297T PL10821297T PL2482849T3 PL 2482849 T3 PL2482849 T3 PL 2482849T3 PL 10821297 T PL10821297 T PL 10821297T PL 10821297 T PL10821297 T PL 10821297T PL 2482849 T3 PL2482849 T3 PL 2482849T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
combination immunotherapy
immunotherapy
combination
Prior art date
Application number
PL10821297T
Other languages
English (en)
Inventor
James Allison
Padmanee Sharma
Sergio A. Quezada
Tihui Fu
Original Assignee
Memorial Sloan-Kettering Cancer Center
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2482849(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan-Kettering Cancer Center, Board Of Regents, The University Of Texas System filed Critical Memorial Sloan-Kettering Cancer Center
Publication of PL2482849T3 publication Critical patent/PL2482849T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL10821297T 2009-09-30 2010-09-30 Skojarzona immunoterapia w leczeniu nowotworu PL2482849T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24743809P 2009-09-30 2009-09-30
PCT/US2010/051008 WO2011041613A2 (en) 2009-09-30 2010-09-30 Combination immunotherapy for the treatment of cancer
EP10821297.8A EP2482849B1 (en) 2009-09-30 2010-09-30 Combination immunotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL2482849T3 true PL2482849T3 (pl) 2018-11-30

Family

ID=43826897

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10821297T PL2482849T3 (pl) 2009-09-30 2010-09-30 Skojarzona immunoterapia w leczeniu nowotworu

Country Status (9)

Country Link
US (6) US8709417B2 (pl)
EP (2) EP3375791A1 (pl)
JP (1) JP5960597B2 (pl)
CN (2) CN102740887B (pl)
AU (2) AU2010303149B2 (pl)
CA (1) CA2775761C (pl)
ES (1) ES2681214T3 (pl)
PL (1) PL2482849T3 (pl)
WO (1) WO2011041613A2 (pl)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
CA2775761C (en) 2009-09-30 2018-08-28 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US9133436B2 (en) 2010-02-04 2015-09-15 The Trustees Of The University Of Pennsylvania ICOS critically regulates the expansion and function of inflammatory human Th17 cells
CN106749662B (zh) * 2011-03-31 2021-06-18 国家医疗保健研究所 抗icos的抗体及其用途
CN102935228B (zh) * 2011-08-15 2015-02-18 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的试剂、其用途及方法
EP2806883B1 (en) * 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
MD4655C1 (ro) * 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
JP6483082B2 (ja) * 2013-03-15 2019-03-13 ジェネンテック， インコーポレイテッド Ｐｄ−１及びｐｄ−ｌ１に関連する状態を治療するためのバイオマーカー及び方法
RU2670804C9 (ru) 2013-09-20 2018-11-28 Бейкер Хьюз Инкорпорейтед Способ применения содержащих металл агентов для модификации поверхности при обработке подземных пластов
EP3046991B1 (en) 2013-09-20 2019-10-30 Baker Hughes, a GE company, LLC Composites for use in stimulation and sand control operations
EP3046987B8 (en) 2013-09-20 2019-06-26 Baker Hughes, a GE company, LLC Use of organophosphorus containing composites for use in well treatment operations
US10227846B2 (en) 2013-09-20 2019-03-12 Baker Hughes, A Ge Company, Llc Method of inhibiting fouling on a metallic surface using a surface modifying treatment agent
EP3046988B1 (en) 2013-09-20 2019-08-21 Baker Hughes, a GE company, LLC Method of using surface modifying treatment agents to treat subterranean formations
US9701892B2 (en) 2014-04-17 2017-07-11 Baker Hughes Incorporated Method of pumping aqueous fluid containing surface modifying treatment agent into a well
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN105744950A (zh) * 2013-11-05 2016-07-06 巴法里安诺迪克有限公司 用于使用表达肿瘤抗原的痘病毒和免疫检查点抑制剂的拮抗剂和/或激动剂治疗癌症的组合疗法
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170000832A1 (en) 2014-02-27 2017-01-05 Viralytics Limited Combination method for treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
US12427173B2 (en) * 2014-03-31 2025-09-30 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
GB201408119D0 (en) * 2014-05-08 2014-06-25 Univ Cork Method
AU2015259516B2 (en) 2014-05-13 2020-05-28 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
CN110354266A (zh) 2014-05-23 2019-10-22 卫材 R&D 管理有限公司 用于治疗癌症的组合疗法
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
EP3309174B1 (en) 2014-07-11 2022-05-11 Ventana Medical Systems, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
JP6767096B2 (ja) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
ES2791950T3 (es) 2015-02-03 2020-11-06 Ventana Med Syst Inc Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
US20180230431A1 (en) * 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
SI3394103T1 (sl) 2015-12-22 2023-10-30 Regeneron Pharmaceuticals, Inc. Kombinacija protiteles proti-PD-1 in bispecifičnih protiteles proti-CD20/proti-CD3 za zdravljenje raka
EP3388514B1 (en) * 2016-02-26 2023-10-25 SCM Lifescience Co., Ltd. Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
EP3443000B1 (en) 2016-04-15 2025-11-12 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
TW202408578A (zh) 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
CN116640214A (zh) * 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
WO2018115859A1 (en) * 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
US20200190191A1 (en) * 2016-12-20 2020-06-18 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
WO2018176144A1 (en) * 2017-03-29 2018-10-04 Sunnybrook Research Institute Engineered t-cell modulating molecules and methods of using same
US20200024351A1 (en) * 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
ES2914311T3 (es) 2017-04-18 2022-06-09 Tempest Therapeutics Inc Compuestos bicíclicos y su uso en el tratamiento del cáncer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
MX2019013648A (es) 2017-05-19 2021-01-08 Wuxi Biologics Shanghai Co Ltd Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
EP3634483A1 (en) * 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
CA3066756A1 (en) * 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN107328620B (zh) * 2017-06-23 2020-06-05 浙江普罗亭健康科技有限公司 用于流式细胞技术的封闭缓冲液及试剂盒
JP2020532991A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
MX2020004540A (es) 2017-10-18 2020-08-03 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019149286A1 (en) 2018-02-05 2019-08-08 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
TW202000891A (zh) 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
KR102815312B1 (ko) 2018-04-17 2025-05-30 템페스트 테라퓨틱스, 인크. 비시클릭 카르복스아미드 및 그의 사용 방법
WO2019229613A1 (en) 2018-05-31 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
JP2021525713A (ja) 2018-05-31 2021-09-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を治療するためのｉｉ型タンパク質アルギニンメチルトランスフェラーゼ阻害剤及びｉｃｏｓ結合タンパク質の組合せ
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
EP3860641A1 (en) 2018-10-05 2021-08-11 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
WO2020185739A1 (en) * 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
KR20230041654A (ko) 2020-05-05 2023-03-24 테온 테라퓨틱스, 인크. 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
TWI877433B (zh) 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
RS66849B1 (sr) 2020-12-28 2025-06-30 Bristol Myers Squibb Co Kompozicije antitela i postupci njihove upotrebe
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
CA3238283A1 (en) 2021-11-15 2023-05-19 Yangxin Fu Fusion protein construct taking interleukin 15 as active ingredient and use thereof
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025223372A1 (en) 2024-04-22 2025-10-30 Fujian Haixi Pharmaceuticals Co., Ltd. Combination comprising a pd-1 inhibitor and a pyridine compound for use in treating solid tumors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
AU774962B2 (en) * 1998-12-03 2004-07-15 Regents Of The University Of California, The Stimulation of T cells against self antigens using CTLA-4 blocking agents
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
ATE366814T1 (de) * 1999-09-21 2007-08-15 Genetics Inst Llc Gl50 moleküle, sowie verwendungen derselben
JP2004501624A (ja) 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
EP2388590A1 (en) * 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
EP1441758A2 (de) * 2001-11-09 2004-08-04 MediGene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) * 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7026164B2 (en) 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
AU2005259958A1 (en) * 2004-06-29 2006-01-12 The Johns Hopkins University Amelioration of drug-induced toxicity
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP3130350A1 (en) * 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
BRPI0811466A2 (pt) * 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US9817054B2 (en) 2012-06-28 2017-11-14 Intel Corporation Electrical margining of multi-parameter high-speed interconnect links with multi-sample probing
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2775761C (en) 2009-09-30 2018-08-28 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
CN106749662B (zh) 2011-03-31 2021-06-18 国家医疗保健研究所 抗icos的抗体及其用途
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
RS60614B1 (sr) * 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos

Also Published As

Publication number Publication date
CN104826106B (zh) 2019-01-11
WO2011041613A3 (en) 2011-08-04
US20190352398A1 (en) 2019-11-21
AU2010303149B2 (en) 2016-08-04
CN102740887A (zh) 2012-10-17
JP5960597B2 (ja) 2016-08-02
US10023637B2 (en) 2018-07-17
AU2016206233A1 (en) 2016-08-04
CN104826106A (zh) 2015-08-12
US8709417B2 (en) 2014-04-29
WO2011041613A2 (en) 2011-04-07
US10167337B2 (en) 2019-01-01
US9375475B2 (en) 2016-06-28
EP3375791A1 (en) 2018-09-19
US20140308299A1 (en) 2014-10-16
US20180251555A1 (en) 2018-09-06
EP2482849A4 (en) 2013-08-07
US20120251556A1 (en) 2012-10-04
EP2482849A2 (en) 2012-08-08
AU2010303149A1 (en) 2012-04-26
CA2775761A1 (en) 2011-04-07
JP2013506690A (ja) 2013-02-28
ES2681214T3 (es) 2018-09-12
CN102740887B (zh) 2015-04-15
CA2775761C (en) 2018-08-28
EP2482849B1 (en) 2018-06-06
US20160244524A1 (en) 2016-08-25
US20220162315A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
PL2482849T3 (pl) Skojarzona immunoterapia w leczeniu nowotworu
IL218575A0 (en) Treatment of cancer
PT2303021T (pt) Compostos para tratamento do cancro
SG173672A1 (en) Novel ortho-aminoamides for the treatment of cancer
IL219073A (en) A drug combination for cancer treatment
IL214746A0 (en) Substituted pyrimidines for the treatment of cancer
IL215767A0 (en) Methods of treatment for solid tumors
SG10201508495VA (en) Combination treatment of cancer
ZA201107879B (en) Composition for the treatment of prostate cancer
IL251083B (en) Compounds and preparations for the treatment of cancer
IL218971A0 (en) Sulfoxide derivatives for the treatment of tumours
SI2605764T1 (sl) Sestavki za zdravljenje raka
IL214349A0 (en) Compositions and methods for the treatment of cancer
IL222958A0 (en) Cancer treatment
ZA201300762B (en) Novel combination therapy for the treatment of cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
ZA201109508B (en) Methods of using corticotropin-releasing factor for the treatment of cancer
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
GB0921757D0 (en) Treatment of cancer
GB2470001A9 (en) The reason of all cancer types
GB201017356D0 (en) Combination treatment of cancer
GB0817056D0 (en) Polypeptide for treatment of cancer
GB201301168D0 (en) Cancer treatment